GE and R2 extend partnership
The first company to commercialize a full-field digital mammography system and the first to deliver mammography CAD have renewed their alliance. GE Medical Systems (Waukesha, WI) and R2 Technology (Sunnyvale, CA) announced Dec. 12 that R2's ImageChecker
The first company to commercialize a full-field digital mammography system and the first to deliver mammography CAD have renewed their alliance. GE Medical Systems (Waukesha, WI) and R2 Technology (Sunnyvale, CA) announced Dec. 12 that R2's ImageChecker CAD system would continue to be distributed with GE's Senographe 2000D full-field digital mammography system. More than 100 such combinations are already operating in clinical sites, according to GE, and there is room for substantial growth. More than 550 Senographe 2000D systems have been installed in the U.S., and all are upgradable to R2's CAD technology. The FDA originally cleared the ImageChecker system in 1998 for use with film-based screening mammography to assist radiologists in minimizing false-negative readings. Supplemental approvals by the FDA allowed the technology to be used in combination with the Senographe 2000D.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
Emerging AI Mammography Model May Enhance Clarity for Initial BI-RADS 3 and 4 Classifications
May 21st 2025In a study involving over 12,000 Asian women, researchers found that an artificial intelligence (AI) model converted over 83 percent of false positives in patients with initial BI-RADS 3 and 4 assessments into benign BI-RADS categories.
